ANVS ANNOVIS BIO INC revenue, earnings and financials
For the quarter ended June 30, 2026, ANNOVIS BIO INC reported revenue of n/a, net income of −$14.8M and diluted EPS of −$0.40; for the fiscal year ended December 2025 revenue was $0.
ANVS annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$29.7M, net income −$28.9M (margin n/a), EPS −$1.40
- Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$26.7M, net income −$24.6M (margin n/a), EPS −$2.31
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$45.0M, net income −$56.2M (margin n/a), EPS −$6.23
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$25.5M, net income −$25.3M (margin n/a), EPS −$3.10
- Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$14.5M, net income −$14.5M (margin n/a), EPS −$1.90
ANVS quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$14.8M, EPS −$0.40
- Quarter ended Mar 31, 2026: revenue $0, net income −$17.6M, EPS −$0.63
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$9.83M, EPS −$0.39
- Quarter ended Sep 30, 2025: revenue n/a, net income −$7.26M, EPS −$0.37
- Quarter ended Jun 30, 2025: revenue n/a, net income −$6.22M, EPS −$0.32
- Quarter ended Mar 31, 2025: revenue $0, net income −$5.54M, EPS −$0.32
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$5.86M, EPS −$0.18
- Quarter ended Sep 30, 2024: revenue n/a, net income −$12.6M, EPS −$0.97
- Quarter ended Jun 30, 2024: revenue n/a, net income −$5.02M, EPS −$0.44
- Quarter ended Mar 31, 2024: revenue $0, net income −$1.07M, EPS −$0.72
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$22.2M, EPS −$2.46
- Quarter ended Sep 30, 2023: revenue n/a, net income −$14.7M, EPS −$1.63
- Quarter ended Jun 30, 2023: revenue n/a, net income −$9.54M, EPS −$1.07
- Quarter ended Mar 31, 2023: revenue $0, net income −$9.74M, EPS −$1.07
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$7.73M, EPS −$0.94
- Quarter ended Sep 30, 2022: revenue n/a, net income −$6.43M, EPS −$0.79
- Quarter ended Jun 30, 2022: revenue n/a, net income −$5.94M, EPS −$0.73
- Quarter ended Mar 31, 2022: revenue $0, net income −$5.23M, EPS −$0.64
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$5.91M, EPS −$0.75
- Quarter ended Sep 30, 2021: revenue n/a, net income −$2.85M, EPS −$0.35
ANVS cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$25.6M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$21.9M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$40.0M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$17.3M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$9.13M, share buybacks n/a
ANVS balance sheet
- Jun 30, 2026: cash $18.7M, total assets $22.0M, total liabilities $26.3M, shareholders' equity −$4.25M
- Mar 31, 2026: cash $14.2M, total assets $16.2M, total liabilities $13.1M, shareholders' equity $3.13M
- Dec 31, 2025: cash $19.5M, total assets $21.1M, total liabilities $4.23M, shareholders' equity $16.9M
- Sep 30, 2025: cash $15.3M, total assets $17.2M, total liabilities $4.03M, shareholders' equity $13.2M
- Jun 30, 2025: cash $17.1M, total assets $21.5M, total liabilities $3.12M, shareholders' equity $18.3M
- Mar 31, 2025: cash $22.2M, total assets $26.7M, total liabilities $2.68M, shareholders' equity $24.1M
- Dec 31, 2024: cash $10.6M, total assets $13.9M, total liabilities $4.62M, shareholders' equity $9.31M
- Sep 30, 2024: cash $12.6M, total assets $14.4M, total liabilities $7.30M, shareholders' equity $7.06M
What is ANVS's revenue?
ANNOVIS BIO INC reported $0 of revenue for the fiscal year ended December 2025.
Is ANVS profitable?
No. ANNOVIS BIO INC lost $49.5M over the last four quarters.
What is ANVS's EPS?
Diluted earnings per share over the last four quarters were −$1.79; −$0.40 in the latest quarter.